

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number
WO 2004/016605 A1

(51) International Patent Classification⁷: C07D 401/04,
A61K 31/506, A61P 25/16, 25/22, 25/24, 9/00

(21) International Application Number:
PCT/JP2003/010360

(22) International Filing Date: 14 August 2003 (14.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002950853 19 August 2002 (19.08.2002) AU

(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, OSAKA 541-8514 (JP).

(72) Inventor; and

(75) Inventor/Applicant (for US only): AKAHANE Atsushi [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, OSAKA 541-8514 (JP).

(74) Agent: TABUSHI, Eiji; c/o Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-AMINOPYRIMIDINE DERIVATIVES AS ADENOSINE A1 AND A2A RECEPTOR ANTAGONISTS



(I)

(57) Abstract: An aminopyrimidine compound of the following formula (I). Wherein R¹ is hydrogen, lower alkyl, cyclo(lower)alkyl which may be interrupted by an oxygen atom or aryl(lower)alkyl, R² is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, amino (lower)alkoxy or piperidinyloxy, R³ is hydrogen, hydroxy, lower alkyl or lower alkoxy, and R⁴ and R⁵ are each hydrogen, lower alkyl or acyl, or a salt thereof. The aminopyrimidine compound (I) and salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression,

dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like



WO 2004/016605 A1

DESCRIPTION

2-AMINOPYRIMIDINE DERIVATIVES AS ADENOSINE A₁ AND A_{2A} RECEPTOR ANTAGONISTS

TECHNICAL FIELD

The present invention relates to a novel aminopyrimidine compound and a salt thereof, which are useful as medicaments.

BACKGROUND ART

2-Aminopyridine compounds to exhibit adenosine receptor antagonism are known (WO 02/14282).

2-Amino-4-phenyl-5-(6-oxo-1,6-dihydro-pyrid-3-yl)-pyrimidine compounds and derivatives thereof are novel, so there has been no knowledge about these compounds. In addition, any aminopyrimidine compounds having both of adenosine A₁ and A_{2a} inhibitory activities are not known.

DISCLOSURE OF INVENTION

The present invention relates to a novel aminopyrimidine compound and a pharmaceutically acceptable salt thereof, which are useful as medicaments; processes for the preparation of said aminopyrimidine compound and a salt thereof; a pharmaceutical composition comprising, as an active ingredient, said aminopyrimidine compound or a pharmaceutically acceptable salt thereof; a use of said aminopyrimidine compound or a pharmaceutically acceptable salt thereof as a medicament; and a method for using said aminopyrimidine compound or a pharmaceutically acceptable salt thereof for therapeutic purposes, which comprises administering said aminopyrimidine compound or a pharmaceutically acceptable salt thereof to a human being or an animal.


The aminopyrimidine compound and a salt thereof are adenosine antagonists (especially, A₁ receptor and A₂ (particularly A_{2a}) receptor dual antagonists) and possess various pharmacological actions such as anticatalepsy action, cognitive enhancing action, analgesic action, locomotor action, antidepressant action, diuretic action, cardioprotective action, cardiotonic action,

vasodilating action (e.g. cerebral vasodilating action, etc.), the action of increasing the renal blood flow, renal protective action, improvement action of renal function, enhancing action of lipolysis, inhibition action of anaphylactic bronchoconstriction, acceleration action of the insulin release, the action of increasing the production of erythropoietin, inhibiting action of platelet aggregation, or the like.

They are useful as cognitive enhancer, antianxiety drug, antidementia drug, psychostimulant, analgesic, cardioprotective agent, antidepressant, ameliorants of cerebral circulation, tranquilizer, drug for heart failure, cardiotonic agent, antihypertensive agent, drug for renal failure (renal insufficiency), drug for renal toxicity, renal protective agent, drug for improvement of renal function, diuretic, drug for edema, antiobesity, antiasthmatic, bronchodilator, drug for apnea, drug for gout, drug for hyperuricemia, drug for sudden infant death syndrome (SIDS), ameliorants of immunosuppressive action of adenosine, antidiabetic agent, drug for ulcer, drug for pancreatitis, drug for Meniere's syndrome, drug for anemia; drug for thrombosis, drug for myocardial infarction, drug for obstruction, drug for arteriosclerosis obliterans, drug for thrombophlebitis, drug for cerebral infarction, drug for transient ischemic attack, drug for angina pectoris, or the like; and useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure; hypertension (e.g. essential hypertension, nephrogenous hypertension, etc.); circulatory insufficiency (acute circulatory insufficiency) caused by, for example, ischemia/reperfusion injury (e.g. myocardial ischemia/reperfusion injury, cerebral

ischemia/reperfusion injury, peripheral ischemia/reperfusion injury, etc.), shock (e.g. endotoxin shock, hemorrhagic shock, etc.), surgical procedure, or the like; post-resuscitation asystole;
bradyarrhythmia;
electro-mechanical dissociation;
hemodynamic collapse;
SIRS (systemic inflammatory response syndrome);
multiple organ failure;
renal failure (renal insufficiency) (e.g. acute renal failure, etc.), renal toxicity [e.g. renal toxicity induced by a drug such as cisplatin, gentamicin, FR-900506 (disclosed in EP-0184162), cyclosporin (e.g. cyclosporinA) or the like; glycerol, etc.], nephrosis, nephritis, edema (e.g. cardiac edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc.);
obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer such as peptic ulcer (e.g. gastric ulcer, duodenal ulcer, etc.), pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus (e.g. mechanical ileus, adynamic ileus, etc.); and
myocardial infarction, thrombosis (e.g. arterial thrombosis, cerebral thrombosis, etc.), obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack, angina pectoris, or the like.

The novel aminopyrimidine compound of the present invention can be shown by the following formula (I).



wherein

R¹ is hydrogen, lower alkyl, cyclo(lower)alkyl which may be interrupted by an oxygen atom or aryl(lower)alkyl,

R² is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, amino(lower)alkoxy or piperidinyloxy,

R³ is hydrogen, hydroxy, lower alkyl or lower alkoxy, and

R⁴ and R⁵ are each hydrogen, lower alkyl or acyl, or a salt thereof.

The preferred embodiments of the aminopyrimidine compound of the present invention represented by the general formula (I) are as follows.

(1) The aminopyrimidine compound of the general formula (I) wherein

R¹ is hydrogen or lower alkyl,

R² is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, amino(lower)alkoxy or piperidinyloxy,

R³ is hydrogen, lower alkyl or lower alkoxy and

R⁴ and R⁵ are each hydrogen,

or a salt thereof.

(2) The aminopyrimidine compound of (1) above

wherein

R¹ is hydrogen, methyl, ethyl, propyl or isopropyl,

R² is hydrogen, fluoro, hydroxy, methoxy, aminoethoxy or piperidinyloxy

R³ is hydrogen, methyl or methoxy, and

R^4 and R^5 are each hydrogen,
or a salt thereof.

(3) The aminopyrimidine compound of the general formula (I)
wherein

R^1 is hydrogen or isopropyl,


R^2 is hydrogen or fluoro,

R^3 is hydrogen, methyl or methoxy, and


R^4 and R^5 are each hydrogen,
or a salt thereof.


The object compound (I) and a salt thereof of the present
invention can be prepared by the following processes.

Process 1



Process 2



Process 3

(IV)


(V)

(VI)

or a salt thereof


or a salt thereof

or a salt thereof



(I)

or a salt thereof



Process 4

(Ic)

(Id)

or a salt thereof

or a salt thereof

Process 5Process 6


wherein

R^1 is hydrogen, lower alkyl, cyclo(lower)alkyl which may be interrupted by an oxygen atom or aryl(lower)alkyl,
 R^{1a} is lower alkyl, cyclo(lower)alkyl which may be interrupted by an oxygen atom or aryl(lower)alkyl,
 R^2 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, amino(lower)alkoxy or piperidinyloxy,
 R^3 is hydrogen, hydroxy, lower alkyl or lower alkoxy,
 R^4 and R^5 are each hydrogen, lower alkyl or acyl,
 R^6 , R^7 and R^{8a} are each lower alkyl,
 R^{8b} is amino(lower)alkyl or cyclo(lower)alkyl which may be interrupted by an oxygen atom,
 R^9 is benzyl which is optionally substituted by suitable substituent(s), selected from the group consisting of halogen,


hydroxy, lower alkyl, lower alkoxy, nitro and cyano, and Y^1 and Y^2 are a leaving group.

The starting compounds or a salt thereof are novel and can be prepared, for example, by the following reaction schemes.


Process A



wherein R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are as defined above, and Y^3 is a leaving group.

Process B


wherein R^2 , R^6 and Y^3 are as defined above.

Process C

wherein R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are as defined above, and


R¹⁰ is arylsulfonyl which may have one or more suitable substituent(s).


Process D



wherein R², R⁶ and Y³ are as defined above,
 Y⁴ is a leaving group, and
 TMS is trimethylsilyl.



Process E





wherein R^1 and R^2 are as defined above, and Y^5 is a leaving group.

Process F




wherein R^2 , R^3 , R^4 and R^5 are as defined above, R^{11} is lower alkyl or benzyl which is optionally substituted by suitable substituent(s), selected from the group consisting of halogen, hydroxy, lower alkyl, lower alkoxy, nitro and cyano,

and

Y^6 is a leaving group, preferably a halogen atom.

Process G




wherein R^2 , R^4 and R^5 are as defined above,

R^{12} is lower alkyl, and

Y^7 is a leaving group.

Process H



wherein R^9 is as defined above.

In addition to the processes as mentioned above, the object compound (I) and a salt thereof can be prepared, for example,

according to the procedures as illustrated in Examples in the present specification or in a manner similar thereto.

The starting compounds can be prepared, for example, according to the procedures as illustrated in Preparations in the present specification or in a manner similar thereto.

The object compound (I) and a salt thereof can be prepared according to the methods as shown in Preparations or Examples, or in a manner similar thereto.

It is to be noted that the object compound (I) may include the geometrical isomer(s) due to the double bond(s) and/or the stereo isomer(s) due to the asymmetric carbon atom(s). In this regard, one isomer can be converted to another according to a conventional method in this field of the art.

It is also to be noted that the solvating form of the compound (I) (e.g. hydrate, etc.) and any form of the crystal of the compound (I) are included within the scope of the present invention.

Suitable salts of the object compound (I) are conventional pharmaceutically acceptable ones and include a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), an organic acid salt (e.g. acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydriodide, sulfate, phosphate, etc.), a salt with an amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.), and the like.

Suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof and which appear in the above and following description in the present specification are explained in detail as follows.

The term "lower" is intended to mean 1 to 6 carbon atom(s) unless otherwise indicated.

Suitable "lower alkyl" may include straight or branched (C1-C6)alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl or the like, in which the preferred one may be methyl, ethyl, propyl or isopropyl.

Suitable "lower alkyl" moiety in the terms "aryl(lower)alkyl" such as phenyl(lower)alkyl may include straight ones such as methyl, ethyl, propyl, butyl, pentyl, hexyl or the like, in which the preferred one may be (C1-C4)alkyl and the more preferred one may be methyl or ethyl.

Suitable "lower alkoxy" may include straight or branched ones such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy or the like, in which the preferred one may be (C1-C4)alkoxy and the more preferred one may be methoxy.

Suitable "cyclo(lower)alkyl" may be cyclo(C3-C8)alkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or the like, in which the preferred one may be cyclohexyl.

Said "cyclo(lower)alkyl" may be interrupted by an oxygen atom, in which the preferred one may be saturated 3-8-membered heteromonocyclic group containing an oxygen atom such as tetrahydrofuranyl or tetrahydropyranyl.

Suitable "acyl" may include "optionally substituted carbonyl" such as lower alkanoyl, substituted lower alkanoyl, cyclo(lower) alkanoyl, optionally substituted benzoyl, or optionally substituted carbamoyl, or "optionally substituted sulfonyl", or the like.

Suitable examples of aforesaid "lower alkanoyl" may include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl or the like, in which the preferred one may be (C1-C4)alkanoyl and the more preferred one may be acetyl.

Suitable examples of aforesaid "substituted lower alkanoyl" may include phenyl(lower)alkanoyl, methoxyphenyl(lower)alkanoyl, phenyloxy(lower)alkanoyl, or the like, in which the preferred one may be phenylacetyl, methoxyphenylacetyl, phenyloxyacetyl, or the like.

Suitable examples of aforesaid "cyclo(lower)alkanoyl" may be cyclopropanoyl, cyclobutanoyl, cyclobutanoyl, cyclopentanoyl, in which the preferred one is cyclohexanoyl.

Suitable examples of aforesaid "optionally substituted benzoyl" may include benzoyl, lower alkyl benzoyl, or the like, in which the preferred one may be benzoyl.

Suitable examples of aforesaid "optionally substituted carbamoyl" may include carbamoyl or N-substituted carbamoyl such as N-(lower)alkylcarbamoyl, N-arylcarbamoyl, N-aryl(lower)alkylcarbamoyl, N-arylsulfonylcarbamoyl, or the like, in which the preferred example of "N-substituted carbamoyl" may be phenylcarbamoyl, tolylcarbamoyl, benzylcarbamoyl, tosylcarbamoyl, or the like.

Suitable examples of aforesaid "optionally substituted sulfonyl" may include sulfinoyl, lower alkylsulfonyl, arylsulfonyl, or the like, in which the preferred example of "substituted sulfonyl" may be mesyl, tosyl, or the like.

Suitable "aryl" may include phenyl, naphthyl, indenyl, anthryl, or the like, in which the preferred one may be (C6-C10) aryl, and the more preferred one may be phenyl.

Suitable "ar(lower)alkyl" may include phenyl(lower)alkyl (e.g. benzyl, phenethyl, etc.), diphenyl(lower)alkyl (e.g. benzhydryl, etc.), triphenyl(lower)alkyl (e.g. trityl, etc.), naphthyl(lower)alkyl, indenyl(lower)alkyl or anthryl(lower)alkyl and the like, in which the preferred one may be phenyl(lower)alkyl, and the more preferred one may be phenyl(C1-C4)alkyl.

Suitable "halogen" may be fluoro, chloro, bromo and iodo,

in which the preferred one may be fluoro.

Suitable "a leaving group" may include halogen (e.g. fluoro, chloro, bromo and iodo), hydroxy, acyloxy such as alkanoyloxy (e.g. acetoxy, propionyloxy, etc.), sulfonyloxy (e.g. mesyloxy, tosyloxy, etc.), or the like, in which the preferred one may be bromo or iodo.

Suitable "arylsulfonyl" may include phenylsulfonyl, tolylsulfonyl, naphthylsulfonyl and the like, and said "arylsulfonyl" may have one or more (preferably 1 to 3) suitable substituent(s) such as aforesaid lower alkoxy, aforesaid halogen, or the like.

The processes for preparing the object aminopyrimidine compound(I) are explained in detail in the following.

Process 1

The compound (Ia) or a salt thereof can be prepared by subjecting the compound (IIa) or a salt thereof to hydrolysis.

Suitable salt of the compound (IIa) can be referred to an acid addition salt as exemplified for the compound (I).

This reaction is carried out in accordance with a conventional method.

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base includes an inorganic base and an organic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamide (e.g. trimethylamine, triethylamine, etc.), hydrazine, picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]-octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.

Suitable acid includes an organic acid (e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid,

trifluoroacetic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.).

The elimination using Lewis acid such as BBr_3 , BCl_3 , BF_3 , AlCl_3 , TiCl_4 or the like is preferably carried out in the presence of cation trapping agents (e.g. anisole, phenol, etc.).

The reaction is usually carried out in a solvent such as water, an alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.

A liquid base or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

Process 2

The compound (Ib) or a salt thereof can be prepared by reacting the compound (Ia) or a salt thereof with the compound (III) or a salt thereof.

Suitable salt of the compound (Ia) can be referred to an acid addition salt as exemplified for the compound (I).

Suitable salt of the compound (III) can be referred to the ones as exemplified for the compound (I).

The present reaction may be carried out in a solvent such as water, phosphate buffer, acetone, chloroform, acetonitrile, nitrobenzene, methylene chloride, ethylene chloride, formamide, N,N-dimethylformamide, methanol, ethanol, sec-butanol, amyl alcohol, diethyl ether, dioxane, tetrahydrofuran, dimethyl sulfoxide, or any other organic solvent which does not adversely affect the reaction, preferably in ones having strong polarities. Among the solvents, hydrophilic solvents may be used in a mixture with water. When the compound (III) is in liquid, it can also be used as a solvent. The reaction is preferably conducted in

the presence of a base, for example, inorganic base such as alkali metal hydroxide, alkali metal carbonate, alkali metal bicarbonate, alkali metal hydride (e.g. sodium hydride, etc.), organic base such as trialkylamine, and the like.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or under heating.

The present reaction is preferably carried out in the presence of alkali metal halide (e.g. sodium iodide, potassium iodide, etc.), alkali metal thiocyanate (e.g. sodium thiocyanate, potassium thiocyanate, etc.), di(lower)alkyl azodicarboxylate (e.g. diethyl azodicarboxylate, diisopropyl azodicarboxylate, etc.) or the like.

When Y¹ is -OH, activation of OH with triphenylphosphine and the like may be necessary.

Process 3

The compound (I) or a salt thereof can be prepared by subjecting the compound (IV) or a salt thereof to formation reaction of pyrimidine ring.

Suitable salt of the compound (IV) and (V) can be referred to the ones as exemplified for the compound (I).

Suitable salt of the compound (VI) can be referred to an acid addition salt as exemplified for the compound (I), in which the preferred one is hydrochloride.

This reaction can be carried out by reacting the compound (IV) or a salt thereof with the compound (V) or a salt thereof, and further reacting with the compound (VI) or a salt thereof.

The reaction may be carried out in a conventional solvent such as water, alcohol (e.g. methanol, ethanol, etc.), acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely affect the reaction. These conventional solvents may also be

used in a mixture with water. In this case, the compound V can also be used as a single solvent. The reaction is preferably conducted in the presence of a base, for example, inorganic base such as alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkali metal bicarbonate (e.g. sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), alkali metal hydride (e.g. sodium hydride), alkali metal alkoxide (e.g. MeONa, EtONa, t-BuOK, etc.) organic base such as trialkylamine, and the like.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or under heating.

Process 4

The compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) or a salt thereof to elimination reaction of alkyl group.

Suitable salts of the compound (Ic) and (Id) can be referred to the ones as exemplified for the compound (I).

This reaction is carried out in accordance with a conventional method such as hydrolysis.

The hydrolysis can be carried out in the same manner as in the aforementioned Process 1, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 1.

The reaction of this process can be also carried out according to a conventional reduction method employed in this field of the art (e.g. chemical reduction, catalytic reduction, etc.).

The reaction temperature is not critical and the reaction is usually carried out at ambient temperature, under warming or under heating.

Process 5

The compound (Ie) or a salt thereof can be prepared by reacting

the compound (Id) or a salt thereof with the compound (VII) or a salt thereof.

Suitable salt of the compound (Id) can be referred to an acid addition salt as exemplified for the compound (I).

Suitable salt of the compound (VII) can be referred to the ones as exemplified for the compound (I).

The reaction of this process can be carried out in the same manner as in the aforementioned Process 2, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 2.

Process 6

The compound (Ia) or a salt thereof can be prepared by subjecting the compound (IIb) or a salt thereof to reduction reaction.

Suitable salts of the compound (IIb) can be referred to the ones as exemplified for the compound (I).

This reaction is carried out in accordance with a conventional hydrogenation or reduction (e.g. chemical reduction, catalytic reduction, etc.) method employed in this field of the art.

The reaction is usually carried out in a solvent such as water, alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, acetic acid, pyridine, or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.

The reaction temperature is not critical and the reaction is usually carried out at ambient temperature, under warming or under heating.

The reaction of this process can be also carried out in the manner similar to that of Process 1 or 4.

Process A

The reactions of steps 1 and 2 can be respectively carried

out by the methods disclosed in Preparations 1 and 2 mentioned later or the similar manners thereto.

The reaction of steps 3 can be carried out in the same manner as in the aforementioned Process 3, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 3.

Process B

The reaction can be carried out by the method disclosed in Preparation 3 mentioned later or the similar manners thereto.

Process C

The reaction of Step 1 can be carried out by the method disclosed in Preparation 2 mentioned later or the similar manners thereto.

The reaction of step 2 can be carried out in the same manner as in the aforementioned Process 3, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 3.

The reaction of steps 3 can be respectively carried out by the method disclosed in Preparations 7 mentioned later or the similar manners thereto.

Process D

The reactions of steps 1, 2 and 3 can be respectively carried out by the methods disclosed in Preparations 8, 9 and 1 mentioned later or the similar manners thereto.

Process E

The reactions of steps 1 and 2 can be respectively carried out by the methods disclosed in Preparations 1 and 2 mentioned later or the similar manners thereto.

Process F

The reactions of steps 1 and 2 can be respectively carried out by the methods disclosed in Preparations 31 and 32 mentioned later or the similar manners thereto.

Process G

The reaction can be respectively carried out by the methods

disclosed in Preparation 33 mentioned later or the similar manners thereto.

Process H

The reactions of steps 1 and 2 can be respectively carried out by the methods disclosed in Preparations 29 and 30 mentioned later or the similar manners thereto.

The object compound (I) of the present invention is an adenosine antagonist and possesses the various pharmacological actions as stated before.

In order to show the usefulness of the compound (I) of the present invention, the pharmacological test result of the representative compound of the present invention is shown in the following.

Test 1 : Adenosine antagonistic activity

[I] Test method

The adenosine antagonistic activity [K_i (nM)] of the test compound was examined by radioligand binding techniques using 8-cyclopentyl-1,3-dipropylxanthine, [dipropyl-2,3- ^3H (N)] (^3H]DPCPX, 4.5nM) for human A_1 receptor and [^3H]CGS 21680 (20nM) for human A_{2a} receptor.

[II] Test compound

5-[2-Amino-4-(4-fluorophenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone (Example 3)

5-[2-Amino-4-(4-fluorophenyl)-5-pyrimidinyl]-1-ethyl-2(1H)-pyridinone (Example 5)

5-(2-Amino-4-phenyl-5-pyrimidinyl)-1-isopropyl-2(1H)-pyridinone (Example 7)

5-(2-Amino-4-phenyl-5-pyrimidinyl)-1-ethyl-2(1H)-pyridinone (Example 8)

5-[2-Amino-4-(2-methoxyphenyl)-5-pyrimidinyl]-
1-isopropyl-2(1H)-pyridinone (Example 12)

5-[2-amino-4-(2-hydroxyphenyl)-5-pyrimidinyl]-
1-isopropyl-2(1H)-pyridinone (Example 17)

5-(2-Amino-4-methyl-6-phenyl-5-pyrimidinyl)-
2(1H)-pyridinone (Example 22)

5-[2-Amino-4-(4-fluorophenyl)-6-methoxy-5-pyrimidinyl]-
1-isopropyl-2(1H)-pyridinone (Example 27)

[III] Test result

Table 1

Test compound (Example No.)	Adenosine receptor binding	
	(K _i :nM)	
	A ₁	A _{2a}
3	11.05	2.37
5	11.02	5.35
7	3.36	0.93
8	2.90	2.62
12	2.16	1.22
17	9.86	4.38
22	35.97	2.59
27	13.87	10.79

Test 2 : Anticatalepsy activity in Mouse

[I] Test method

The test compound (3.2mg/kg) was administered orally with ddY mice (n=7). Then, haloperidol (0.32mg/kg) was injected intraperitoneally 30 min. after the administration of the compound. Thirty min. after the injection, the cataleptic responses of mice were measured. The forelimbs of each mouse were placed on a 3 cm high, 3 mm wide horizontal bar, and the duration of cataleptic posture was measured for up to 30 sec.

[II] Test compound

5-[2-Amino-4-(4-fluorophenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone (Example 3)

5-[2-Amino-4-(4-fluorophenyl)-5-pyrimidinyl]-1-ethyl-2(1H)-pyridinone (Example 5)

5-(2-Amino-4-phenyl-5-pyrimidinyl)-1-isopropyl-2(1H)-pyridinone (Example 7)

5-(2-Amino-4-phenyl-5-pyrimidinyl)-1-ethyl-2(1H)-pyridinone (Example 8)

5-[2-Amino-4-(2-methoxyphenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone (Example 12)

5-(2-Amino-4-methyl-6-phenyl-5-pyrimidinyl)-2(1H)-pyridinone (Example 22)

[III] Test result

Table 2

Test compound (Example No.)	Manifestation rate of catalepsy (number of mouse)
3	0/7
5	0/7
7	1/7
8	1/7
12	1/7
22	0/7

The aminopyrimidine compound (I) and a salt thereof of this invention are useful as adenosine antagonists (especially, A₁ receptor and A₂ (particularly A_{2a}) receptor dual antagonists) and for the prevention and/or the treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease, heart failure, hypertension, circulatory insufficiency, post-resuscitation, asystole, bradyarrhythmia, electro-mechanical dissociation, hemodynamic collapse, SIRS (systemic inflammatory response

syndrome), multiple organ failure, renal failure (renal insufficiency), renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer, pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack, angina pectoris, and the like.

Adenosine antagonists can be useful for Parkinson's disease by co-administrating with L-3,4-dihydroxy-phenylalanine (L-DOPA), which is the most popular drug for Parkinson's disease (R. Grondin et al, *Neurology*, **52**, 1673-1677 (1999)). So the combination use of the pyridazine compound (I) and a salt thereof of this invention with L-DOPA may be also useful for treatment and/or prevention of Parkinson's disease with decreasing or reducing the side effect such as the onset of dyskinesia eliciting by the long-term application of L-DOPA, and so on.

And additionally, as to a series of the compounds disclosed in our previous patents and patent applications of this field (e.g. WO 99/24424, WO 02/18382, WO 02/100864, WO 03/039451, WO 03/057689, etc.), the combination use with L-DOPA may be also useful same as mentioned above.

The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in a solid, semisolid or liquid form, which contains the aminopyrimidine compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation. The active ingredient may be compounded, for example, with the usual non-toxic,

pharmaceutically acceptable carriers for tablets, pellets, troches, capsules, suppositories, creams, ointments, aerosols, powders for insufflation, solutions, emulsions, suspensions, and any other form suitable for use. In addition, auxiliary, stabilizing agents, thickening agents, coloring agents and perfumes may be used where necessary. The aminopyrimidine compound (I) or a pharmaceutically acceptable salt thereof is included in a pharmaceutical composition in an amount sufficient to produce the desired aforesaid pharmaceutical effect upon the process or condition of diseases.

For applying the composition to a human being or an animal, it is preferable to apply it by intravenous, intramuscular, pulmonary or oral administration, or insufflation. While the dosage of therapeutically effective amount of the aminopyrimidine compound (I) varies depending on the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.01 - 100 mg of the aminopyrimidine compound (I) per kg weight of a human being or an animal, in the case of intramuscular administration, a daily dose of 0.1 - 100 mg of the aminopyrimidine compound (I) per kg weight of a human being or an animal, and in case of oral administration, a daily dose of 0.1 - 100 mg of the aminopyrimidine compound (I) per kg weight of a human being or an animal is generally given for the prevention and/or treatment of the aforesaid diseases.

The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.

The abbreviations, symbols and terms used in the Preparations and Examples have the following meanings.

AcOH	acetic acid
CH ₂ Cl ₂	dichloromethane

CHCl ₃	chloroform
DME	1,2-dimethoxyethane
DMF	N,N-dimethylformamide
DMSO	dimethyl sulfoxide
Et ₃ N	triethylamine
EtOAc	ethyl acetate
EtOH	ethanol
MeOH	methanol
THF	tetrahydrofuran
HCl	hydrochloric acid
H ₂ SO ₄	sulfuric acid
K ₂ CO ₃	potassium carbonate
MgSO ₄	magnesium sulfate
NaH	sodium hydride
NaHCO ₃	sodium hydrogen carbonate
NaOH	sodium hydroxide
NaOMe	sodium methoxide
Pd/C	palladium on carbon

Preparation 1

To a mixture of 5-bromo-2-methoxypyridine (21.8 g), ethynylbenzene (15.4 g), dichlorobis(triphenylphosphine)-palladium(II) (814 mg) and copper(I) iodide (221 mg) in DMF (109 ml) was added dropwise Et₃N (21.0 ml) at ambient temperature under nitrogen atmosphere. The mixture was then heated at 60–65°C for 4 hours under nitrogen atmosphere. After being cooled to ambient temperature, the reaction mixture was poured into water and extracted with EtOAc (x2). The combined extracts were washed successively with water and brine, dried over anhydrous MgSO₄ and concentrated under reduced pressure. The residue was purified by silica-gel column chromatography (n-hexane, n-hexane-EtOAc 50:1) to give 2-methoxy-5-(phenylethynyl)pyridine (18.07 g) as oil.

NMR (CDCl₃, δ): 3.96 (3H, s), 6.73 (1H, d, J=8.6 Hz), 7.33-7.37 (3H, m), 7.50-7.55 (2H, m), 7.69 (1H, dd, J=8.6, 2.3 Hz), 8.35 (1H, d, J=2.3 Hz).

ESI/MS: 210 [M+H]⁺

Preparation 2

To a solution of 2-methoxy-5-(phenylethynyl)pyridine (18.0 g) in AcOH (36 ml) was added dropwise conc. H₂SO₄ (90 ml) and the mixture was heated to reflux for 2 hours. After being cooled to ambient temperature, the reaction mixture was poured into ice, neutralized with aqueous NaOH solution and extracted with EtOAc (x2). The combined extracts were washed successively with water and brine, dried over anhydrous MgSO₄ and concentrated under reduced pressure. The crude material was purified by silica-gel column chromatography (n-hexane-EtOAc, 5:1) to give colorless crystals of 2-(6-methoxy-3-pyridyl)-1-phenylethanone (8.70 g).

NMR (CDCl₃, δ): 3.92 (3H, s), 4.22 (2H, s), 6.73 (1H, d, J=8.5 Hz), 7.46-7.51 (3H, 3), 7.56-7.60 (1H, m), 8.00-8.05 (3H, m).
APCI/MS: 228 [M+H]⁺.

Preparation 3

A solution of acetophenone (1.85 g) in dioxane (6 ml) was added dropwise to a solution of lithium bis(trimethylsilyl)amide in THF (1.0M, 30.8 ml) at 5°C over a period of 15 minutes, under nitrogen atmosphere. A solution of tri-tert-butylphosphine (15.6 mg) and tris(dibenzylideneacetone)dipalladium(0) (353 mg) in dioxane (16 ml) was added at ambient temperature, followed by 5-bromo-2-methoxypyridine (1.54 g) in dioxane (8 ml). The mixture was then heated at 90°C for 2 hours. The reaction mixture was cooled to ambient temperature and was partitioned between 1 N HCl and CH₂Cl₂. After an additional extraction with CH₂Cl₂, the combined extracts were washed with water, dried over anhydrous MgSO₄ and concentrated under reduced pressure to afford an oil, which was then purified by silica-gel column chromatography

(n-hexane-EtOAc, 10:1) to give 2-(6-methoxy-3-pyridyl)-1-phenylethanone (0.92 g).

ESI/MS: 250 [M+Na]⁺.

Preparation 4

A mixture of 2-(6-methoxy-3-pyridyl)-1-phenylethanone (950 mg) and DMF-dimethylacetal (1.11 ml) was heated under nitrogen atmosphere at 100°C for 1.5 hours. Volatiles were removed under reduced pressure and the residue was dissolved in EtOH. To the solution was added guanidine HCl (481 mg) followed by NaOMe in MeOH (28% w/w, 1.61 ml) and the mixture was heated to reflux for 1 hour. The reaction mixture was poured into ice/water, and precipitates were filtered, washed with water and dried to give crude material, which was then purified by silica-gel column chromatography (CHCl₃-EtOAc, 10:3) to give 5-(6-methoxy-3-pyridyl)-4-phenyl-2-pyrimidinamine (478 mg) as colorless crystals.

NMR (DMSO-d₆, δ): 3.82 (3H, s), 6.70 (1H, s), 6.85 (2H, s), 7.30-7.35 (6H, m), 7.95 (1H, d, J=2.4 Hz), 8.27 (1H, s).

ESI/MS: 279 [M+H]⁺, 301 [M+Na]⁺.

Preparation 5

1-Phenyl-2-[6-(phenylsulfonyl)-3-pyridyl]ethanone was obtained as yellow solid according to a similar manner to that of Preparation 2.

NMR (DMSO-d₆, δ): 4.64 (2H, s), 7.57-7.75 (6H, m), 7.97-8.23 (5H, m), 8.21 (1H, d, J=8.0 Hz), 8.59 (1H, d, J=1.7 Hz)

ESI/MS: 360 [M+Na]⁺.

Preparation 6

4-Phenyl-5-[6-(phenylsulfonyl)-3-pyridyl]-2-pyrimidinamine was obtained according to a similar manner to that of Preparation 4.

NMR (DMSO-d₆, δ): 7.09 (2H, brd.s), 7.24-7.34 (5H, m), 7.64-7.74 (3H, m), 7.82 (1H, dd, J=8.2, 2.2 Hz), 7.91-7.96 (2H, m), 8.08

(1H, d, J=8.2 Hz), 8.39 (1H, s), 8.39 (1H, d, J=2.2 Hz).

ESI/MS: 411 [M+Na]⁺.

Preparation 7

A mixture of 4-phenyl-5-[6-(phenylsulfonyl)-3-pyridyl]-2-pyrimidinamine (1.89 g) and NaOMe in MeOH (28% w/w, 1.89 ml) in dioxane (38 ml) was heated at 100°C for 1 hour. The mixture was poured into ice, and precipitates were collected by filtration, washed with water and dried to afford 1.20 g of crude material, which was purified by silica-gel column chromatography (CHCl₃-EtOAc, 10:1 - 5:1) to give colorless crystals of 5-(6-methoxy-3-pyridyl)-4-phenyl-2-pyrimidinamine.

ESI/MS: 301 [M+Na]⁺.

Preparation 8

To a solution of 5-bromo-2-methoxypyridine (30.4 g) and trimethylsilylacetylene (25.9 ml) in THF (60 ml) was added dichlorobis(triphenylphosphine)palladium(II) (1.13 g) and copper(I) iodide (308 mg) under nitrogen atmosphere. To the mixture was added dropwise a solution of Et₃N (29.2 ml) in THF (16 ml) at 20-23°C over a period of 10 minutes. The mixture was then heated to reflux for 4 hours and 50 minutes. The reaction mixture was poured into a mixture of water and n-hexane and the organic layer was separated. After an additional extraction with n-hexane, the combined extracts were washed with water, dried over anhydrous MgSO₄ and evaporated under reduced pressure. The crude material was purified by silica-gel column chromatography (n-hexane-EtOAc, 20:1) to give 2-methoxy-5-[(trimethylsilyl)ethynyl]pyridine (26.64 g) as an oil.

NMR (CDCl₃, δ): 0.27 (9H, s), 3.94 (3H, s), 6.67 (1H, d, J=8.5 Hz), 7.61 (1H, dd, J=8.5, 2.4 Hz), 8.28 (1H, d, J=2.4 Hz).

Preparation 9

A mixture of 2-methoxy-5-[(trimethylsilyl)ethynyl]pyridine (26.6 g) and K₂CO₃ (21.5 g) in MeOH was stirred at ambient temperature for 2 hours and 10 minutes. The reaction mixture was poured into

a mixture of ice and water and extracted with n-hexane (x2). The combined extracts were washed with water, dried over anhydrous MgSO_4 and concentrated under reduced pressure. The crude material was purified by silica-gel column chromatography (n-hexane) to afford 5-ethynyl-2-methoxypyridine (13.9 g) as an oil.

NMR (CDCl_3 , δ): 3.11(1H, s), 3.95(3H, s), 6.65(1H, d, $J=8.4$ Hz), 7.64(1H, dd, $J=8.4, 2.4$ Hz), 8.31(1H, d, $J=2.2$ Hz).

Preparation 10

5-[(4-Fluorophenyl)ethynyl]-2-methoxypyridine was obtained as colorless crystals according to a similar manner to that of Preparation 1.

NMR (CDCl_3 , δ): 3.96(3H, s), 6.73(1H, d, $J=8.5$ Hz), 7.00-7.09(2H, m), 7.45-7.53(2H, m), 7.67(1H, dd, $J=8.5, 2.0$ Hz), 8.34(1H, d, $J=2.0$ Hz).

ESI/MS: 228 $[\text{M}+\text{H}]^+$.

Preparation 11

1-(4-Fluorophenyl)-2-(6-methoxy-3-pyridyl)ethanone was obtained as colorless crystals according to a similar manner to that of Preparation 2.

NMR (CDCl_3 , δ): 3.92(3H, s), 4.19(2H, s), 6.74(1H, d, $J=8.5$ Hz), 7.11-7.21(2H, m), 7.48(1H, dd, $J=8.5, 2.5$ Hz), 7.99-8.09(3H, m).

ESI/MS: 268 $[\text{M}+\text{Na}]^+$.

Preparation 12

4-(4-Fluorophenyl)-5-(6-methoxy-3-pyridyl)-2-pyrimidinamine was obtained according to a similar manner to that of Preparation 4.

NMR ($\text{DMSO}-d_6$, δ): 3.83(3H, s), 6.73(1H, d, $J=8.6$ Hz), 6.88(2H, brd.s), 7.12-7.22(2H, m), 7.31-7.41(3H, m), 7.97(1H, d, $J=2.4$ Hz), 7.28(1H, s).

Preparation 13

5-[(4-Fluorophenyl)ethynyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation

1.

NMR (CDCl₃, δ): 1.39 (6H, d, J=6.9 Hz), 5.20-5.34 (1H, m), 6.54 (1H, d, J=9.2 Hz), 7.00-7.09 (2H, m), 7.36 (1H, dd, J=9.2, 2.4 Hz), 7.43-7.50 (2H, m), 7.59 (1H, d, J=2.4 Hz).

ESI/MS: 278 [M+Na]⁺.

Preparation 14

5-[2-(4-Fluorophenyl)-2-oxoethyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 2.

NMR (CDCl₃, δ): 1.35 (6H, d, J=6.7 Hz), 4.01 (2H, s), 5.22-5.35 (1H, m), 6.62 (1H, d, J=10.0 Hz), 7.12-7.27 (4H, m), 7.99-8.07 (2H, m).

ESI/MS: 296 [M+Na]⁺.

Preparation 15

1-Ethyl-5-(phenylethynyl)-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 1.

NMR (CDCl₃, δ): 1.39 (3H, t, J=7.1 Hz), 4.00 (2H, q, J=7.1 Hz), 6.54 (1H, d, J=9.2 Hz), 7.32-7.49 (6H, m), 7.58 (1H, d, J=2.4 Hz)

ESI/MS: 223 [M+Na]⁺

Preparation 16

1-Ethyl-5-(2-oxo-2-phenylethyl)-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 2.

NMR (CDCl₃, δ): 1.35 (3H, t, J=7.2 Hz), 3.98 (2H, q, J=7.2 Hz), 4.05 (2H, s), 6.57 (1H, d, J=9.1 Hz), 7.18-7.27 (2H, m), 7.47-7.62 (3H, m), 7.97-8.02 (2H, m)

ESI/MS: 264 [M+Na]⁺

Preparation 17

1-Isopropyl-5-(phenylethynyl)-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 1.

NMR (CDCl₃, δ): 1.37 (6H, t, J=7.0 Hz), 5.21-5.34 (1H, m), 6.55 (1H, d, J=9.1 Hz), 7.33-7.41 (4H, m), 7.46-7.51 (2H, m), 7.60 (1H, d, J=2.3 Hz)

ESI/MS: 260 [M+Na]⁺

Preparation 18

1-Isopropyl-5-(2-oxo-2-phenylethyl)-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 2.

NMR (CDCl₃, δ): 1.34 (6H, d, J=6.9 Hz), 4.08 (2H, s), 5.21-5.35 (1H, m), 6.56 (1H, d, J=10.0 Hz), 7.18-7.27 (2H, m), 7.46-7.62 (3H, m), 7.98-8.02 (2H, m)

ESI/MS: 256 [M+Na]⁺

Preparation 19

1-Isopropyl-5-[(2-methoxyphenyl)ethynyl]-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 1.

NMR (CDCl₃, δ): 1.39 (6H, d, J=6.8 Hz), 3.82 (3H, s), 5.27 (1H, m), 6.55 (1H, d, J=9.5 Hz), 6.89 (1H, dd, J=9.5, 2.3 Hz), 7.00-7.10 (2H, m), 7.21-7.37 (2H, m), 7.61 (1H, d, J=2.3 Hz)

ESI/MS: 290 [M+Na]⁺

Preparation 20

1-Isopropyl-5-[2-(2-methoxyphenyl)-2-oxoethyl]-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 2.

NMR (CDCl₃, δ): 1.31 (6H, d, J=7.0 Hz), 3.86 (3H, s), 4.06 (2H, s), 5.21-5.34 (1H, m), 6.56 (1H, d, J=10.1 Hz), 7.12-7.23 (3H, m), 7.41 (1H, t, J=7.9 Hz), 7.50-7.60 (2H, m)

ESI/MS: 286 [M+H]⁺, 308 [M+Na]⁺

Preparation 21

1-Isopropyl-5-[(3-methoxyphenyl)ethynyl]-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 1.

NMR (CDCl₃, δ): 1.38 (6H, d, J=6.8 Hz), 3.83 (3H, s), 5.24 (1H, m), 6.54 (1H, d, J=10.3 Hz), 6.85-6.91 (2H, m), 7.27-7.44 (3H, m), 7.57 (1H, d, J=2.4 Hz)

ESI/MS: 290 [M+Na]⁺

Preparation 22

1-Isopropyl-5-[2-(3-methoxyphenyl)-2-oxoethyl]-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 2.

NMR (CDCl₃, δ): 1.31 (6H, d, J=6.9 Hz), 3.87 (3H, s), 4.05 (2H, s), 5.21-5.34 (1H, m), 6.56 (1H, d, J=10.0 Hz), 7.13-7.22 (3H, m), 7.37-7.60 (3H, m)

ESI/MS: 284 [M-H]⁻

Preparation 23

1-Isopropyl-5-[(4-methoxyphenyl)ethynyl]-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 1.

NMR (CDCl₃, δ): 1.36 (6H, d, J=6.9 Hz), 3.82 (3H, s), 5.18-5.30 (1H, m), 6.54 (1H, d, J=9.5 Hz), 6.90 (1H, dd, J=9.5, 2.4 Hz), 7.00-7.10 (2H, m), 7.22-7.27 (2H, m), 7.61 (1H, d, J=2.4 Hz)

ESI/MS: 290 [M+Na]⁺

Preparation 24

1-Isopropyl-5-[2-(4-methoxyphenyl)-2-oxoethyl]-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 2.

NMR (CDCl₃, δ): 1.34 (6H, d, J=6.9 Hz), 3.89 (3H, s), 4.02 (2H, s), 5.20-5.34 (1H, m), 6.55 (1H, d, J=10.0 Hz), 6.93-7.00 (2H, m), 7.18-7.24 (2H, m), 7.95-8.02 (2H, m)

ESI/MS: 286 [M+H]⁺, 308 [M+Na]⁺

Preparation 25

5-[(2-Fluorophenyl)ethynyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 1.

NMR (CDCl₃, δ): 1.32 (6H, d, J=6.9 Hz), 5.21-5.34 (1H, m), 6.55 (1H, d, J=9.2 Hz), 7.10-7.16 (2H, m), 7.28-7.43 (3H, m), 7.63 (1H, d, J=2.4 Hz)

ESI/MS: 278 [M+Na]⁺

Preparation 26

5-[2-(2-Fluorophenyl)-2-oxoethyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 2.

NMR (CDCl₃, δ): 1.34 (6H, d, J=6.9 Hz), 4.05 (2H, d, J=2.8 Hz), 5.20-5.34 (1H, m), 6.55 (1H, d, J=10.1 Hz), 7.12-7.30 (4H, m), 7.54-7.58 (1H, m), 7.88 (1H, td, J=7.6, 1.8 Hz)

ESI/MS: 274 [M+H]⁺, 296 [M+Na]⁺

Preparation 27

5-[(3-Fluorophenyl)ethynyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 1.

NMR (CDCl₃, δ): 1.39 (6H, d, J=6.9 Hz), 5.20-5.34 (1H, m), 6.55 (1H, d, J=9.5 Hz), 7.00-7.05 (1H, m), 7.15-7.04 (4H, m), 7.61 (1H, d, J=2.3 Hz)

ESI/MS: 278 [M+Na]⁺

Preparation 28

5-[2-(3-Fluorophenyl)-2-oxoethyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 2.

NMR (CDCl₃, δ): 1.35 (6H, d, J=6.7 Hz), 4.06 (2H, s), 5.21-5.35 (1H, m), 6.57 (1H, d, J=10.2 Hz), 7.17-7.22 (2H, m), 7.27-7.32 (1H, m), 7.47-7.56 (1H, m), 7.65-7.71 (1H, m), 7.76-7.81 (1H, m)

ESI/MS: 274 [M+H]⁺, 296 [M+Na]⁺

Preparation 29

To a solution of 2,5-dibromopyridine (6.50 g) and (4-methoxyphenyl)methanol (11.2 g) in DME (65 ml) was added 60%

NaH in mineral oil (3.25 g) under ice cooling and the mixture was warmed up to 25°C. The mixture was then heated to reflux for 4.5 hours. The reaction mixture was poured into water (300 ml) and extracted twice with EtOAc. The combined extracts were washed with brine, dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane-EtOAc, 50:1) to afford 5-bromo-2-[(4-methoxybenzyl)oxy]pyridine (7.61 g) as colorless crystals. NMR (DMSO-d₆, δ): 3.80 (3H, s), 5.26 (2H, s), 6.68 (1H, d, J=8.6 Hz), 6.86-6.94 (2H, m), 7.34-7.41 (2H, m), 7.63 (1H, dd, J=8.6, 2.4 Hz), 8.20 (1H, d, J=2.4 Hz). ESI/MS: 316 and 318 [M+Na]⁺

Preparation 30

Under nitrogen atmosphere, a solution of 5-bromo-2-[(4-methoxybenzyl)oxy]pyridine (1.34 g) in THF (5.4 ml) was cooled in a dry-ice/acetone bath to -78°C. To this was added a solution of butyllithium in hexane (1.59 M, 2.87 ml) at -70 ~ -78°C over a period of 5 minutes. After the solution was stirred at -70 ~ -78°C for 2 hours, triisopropyl borate (1.29 g) was added to the solution at -75 ~ -65°C over a period of 5 minutes and the mixture was stirred at -75 ~ 10°C. The reaction mixture was poured into ice/water and pH was adjusted to 7. Precipitates were filtered, washed with water and dried to give {6-[(4-methoxybenzyl)oxy]-3-pyridyl}boronic acid (1.07 g) as colorless powder.

NMR (DMSO-d₆, δ): 3.75 (3H, s), 5.28 (2H, s), 6.78 (1H, d, J=8.6 Hz), 6.93 (2H, d, J=8.7 Hz), 7.38 (2H, d, J=8.7 Hz), 8.01 (1H, dd, J=8.7, 2.0 Hz), 8.13 (2H, s), 8.52 (1H, d, J=2.0 Hz). ESI/MS: 258 [M-H]⁻

Preparation 31

A solution of 4-methyl-6-phenyl-2-pyrimidinamine (5.38 g) and N-iodosuccinimide (8.50 g) in DMF (54 ml) was heated at 50°C for 6.5 hours. The reaction mixture was partitioned between water

and EtOAc. After an additional extraction with EtOAc, the combined extracts were washed with sodium thiosulfate solution, water and brine, dried over MgSO_4 and concentrated under reduced pressure to afford the crude material, which was purified by silica gel column chromatography (CHCl_3 -MeOH, 50:1) to afford 5-iodo-4-methyl-6-phenyl-2-pyrimidinamine (4.34 g) as colorless crystals.

NMR (DMSO-d_6 , δ): 2.51 (3H, s), 6.81 (2H, s), 7.44 (5H, s)

ESI/MS: 312 $[\text{M}+\text{H}]^+$

Preparation 32

Under N_2 atmosphere, a mixture of 5-iodo-4-methyl-6-phenyl-2-pyrimidinamine (2.23 g), (6-methoxy-3-pyridyl)boronic acid (1.21 g), tetrakis(triphenylphosphine)palladium (0) (414 mg) and 2M sodium carbonate (8.25 ml) in DME (25 ml) was heated to reflux for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between water and EtOAc. After an additional extraction with EtOAc, the combined extracts were washed with brine, dried over MgSO_4 and concentrated under reduced pressure. The residue (2.74 g) was purified by silica gel column chromatography (n-hexane-EtOAc, 3:1) to afford 5-(6-methoxy-3-pyridyl)-4-methyl-6-phenyl-2-pyrimidinamine (1.57 g) as colorless crystals.

mp: 171-172°C (EtOAc)

NMR (DMSO-d_6 , δ): 2.12 (3H, s), 3.80 (3H, s), 6.71 (2H, br s), 6.74 (1H, d, $J=8.5$ Hz), 7.16-7.26 (5H, m), 7.47 (1H, dd, $J=8.5$, 2.4 Hz), 7.83 (1H, d, $J=2.5$ Hz)

ESI/MS: 293 $[\text{M}+\text{H}]^+$, 315 $[\text{M}+\text{Na}]^+$

Preparation 33

To a solution of 2-amino-6-(4-fluorophenyl)-4-pyrimidinol (2.62 g) in DMF (60 ml) was added 60% NaH in mineral oil (564 mg) at 5°C and the mixture was stirred at the same temperature for 10 minutes. Then iodomethane (1.99 g) was added to the mixture and stirred at 25°C for 15 hours. The reaction mixture was poured

into water and precipitates were collected by filtration, washed with water and dried to give crude material (2.14 g). Purification by silica gel column chromatography (CHCl_3 -MeOH, 50:1) gave 4-(4-fluorophenyl)-6-methoxy-2-pyrimidinamine (1.56 g) as colorless crystals.

NMR ($\text{DMSO}-d_6$, δ): 3.29 (3H, s), 6.21 (1H, s), 7.22-7.32 (4H, m), 7.97-8.08 (2H, m)

Preparation 34

4-(4-Fluorophenyl)-5-iodo-6-methoxy-2-pyrimidinamine was obtained according to a similar manner to that of Preparation 31.

NMR ($\text{DMSO}-d_6$, δ): 3.37 (3H, s), 7.20-7.31 (2H, m), 7.43 (2H, br s), 7.48-7.58 (2H, m)

ESI/MS: 346 $[\text{M}+\text{H}]^+$, 368 $[\text{M}+\text{Na}]^+$

Preparation 35

4-(4-Fluorophenyl)-6-methoxy-5-{6-[(4-methoxybenzyl)oxy]-3-pyridyl}-2-pyrimidinamine was obtained according to a similar manner to that of Preparation 32.

ESI/MS: 455 $[\text{M}+\text{H}]^+$

Example 1

A mixture of 5-(6-methoxy-3-pyridyl)-4-phenyl-2-pyrimidinamine (2.03 g) and 6N HCl (9 ml) in dioxane (20 ml) was heated to reflux for 4 hours. The reaction mixture was poured into a mixture of ice and water and the mixture was neutralized with K_2CO_3 . Precipitates were filtered, washed with water and dried to afford 5-(2-amino-4-phenyl-5-pyrimidinyl)-2(1H)-pyridinone.

NMR ($\text{DMSO}-d_6$, δ): 6.15 (1H, d, $J=9.4$ Hz), 6.81 (2H, brd.s), 6.97 (1H, dd, $J=9.4, 2.4$ Hz), 7.23 (1H, d, $J=2.4$ Hz), 7.32-7.45 (5H, m), 8.24 (1H, s), 11.65 (1H, brd.s).

ESI/MS: 287 $[\text{M}+\text{Na}]^+$.

Example 2

5-[2-Amino-4-(4-fluorophenyl)-5-pyrimidinyl]-2(1*H*)-pyridinone was obtained according to a similar manner to that of Example 1.

NMR (DMSO- d_6 , δ): 6.19 (1H, d, $J=9.4$ Hz), 6.80 (2H, brd.s), 6.98 (1H, dd, $J=9.4$, 2.7 Hz), 7.16-7.25 (3H, m), 7.42-7.50 (2H, m), 8.23 (1H, s), 11.64 (1H, brd.s).

ESI/MS: 305 [M+Na]⁺.

Example 3

To a suspension of 5-(2-amino-4-phenyl-5-pyrimidinyl)-2(1*H*)-pyridinone (1.40 g) in DMF (28 ml) was added NaH (60% in mineral oil, 218 mg) at 5°C and the resulting mixture was stirred at the same temperature for 15 minutes. Then, isopropyl iodide (0.743 ml) was added to the mixture and stirred at 5°C for 15 minutes and at ambient temperature overnight. The reaction mixture was poured into a mixture of ice and water, and extracted with EtOAc (x2). The combined extracts were washed with successively with water and brine, dried over anhydrous MgSO₄ and concentrated under reduced pressure. The crude material was purified by silica-gel column chromatography (CHCl₃-MeOH, 50:1) to afford pale yellow crystals of 5-[2-amino-4-(4-fluorophenyl)-5-pyrimidinyl]-1-isopropyl-2(1*H*)-pyridinone (283 mg). mp: 258-259°C (90% EtOH).

NMR (DMSO- d_6 , δ): 1.12 (6H, d, $J=6.8$ Hz), 4.91-5.05 (1H, m), 6.29 (1H, d, $J=9.2$ Hz), 6.84 (2H, brd.s), 7.10 (1H, dd, $J=9.2$, 2.5 Hz), 7.15-7.27 (3H, m), 7.40-7.47 (3H, m), 8.29 (1H, s).

ESI/MS: 347 [M+Na]⁺.

Elemental Analysis for C₁₈H₁₇FN₄O

Calcd.: C, 66.65; H, 5.28; N, 17.27

Found : C, 66.66; H, 5.34; N, 17.18

Example 4

5-[2-Amino-4-(4-fluorophenyl)-5-pyrimidinyl]-1-*n*-propyl-2(1*H*)-pyridinone was obtained according to a similar manner to that of Example 3.

mp: 210-211°C (90% EtOH).

NMR (DMSO-d₆, δ): 0.77 (3H, t, J=7.4 Hz), 1.47-1.65 (2H, m), 3.78 (2H, t, J=7.1 Hz), 6.25 (1H, d, J=9.3 Hz), 6.83 (2H, brd.s), 6.99 (1H, dd, J=9.3, 2.5 Hz), 7.21 (2H, t, J=8.9 Hz), 7.42-7.49 (2H, m), 7.56 (1H, d, J=2.5 Hz), 8.25 (1H, s).

ESI/MS: 347 [M+Na]⁺.

Elemental Analysis for C₁₈H₁₇FN₄O

Calcd.: C, 66.65; H, 5.28; N, 17.27

Found : C, 66.45; H, 5.34; N, 17.02

Example 5

5-[2-Amino-4-(4-fluorophenyl)-5-pyrimidinyl]-1-ethyl-2(1H)-pyridinone was obtained according to a similar manner to that of Example 3.

mp: 232-233°C (90% EtOH).

NMR (DMSO-d₆, δ): 1.14 (3H, t, J=7.1 Hz), 3.85 (2H, q, J=7.1 Hz), 6.24 (1H, d, J=9.3 Hz), 6.84 (2H, brd.s), 6.96 (1H, dd, J=9.3, 2.5 Hz), 7.21 (2H, td, J=8.0, 1.9 Hz), 7.42-7.50 (2H, m), 7.61 (1H, d, J=2.5 Hz), 8.27 (1H, s).

ESI/MS: 333 [M+Na]⁺.

Elemental Analysis for C₁₇H₁₅FN₄O

Calcd.: C, 65.80; H, 4.87; N, 18.05

Found : C, 65.79; H, 4.95; N, 17.95

Example 6

5-[2-Amino-4-(4-fluorophenyl)-5-pyrimidinyl]-1-methyl-2(1H)-pyridinone was obtained according to a similar manner to that of Example 3.

mp: 247-248°C (90% EtOH).

NMR (DMSO-d₆, δ): 3.42 (3H, s), 6.21 (1H, d, J=9.3 Hz), 6.82-6.88 (3H, m), 7.21 (2H, t, J=8.0 Hz), 7.44-7.53 (2H, m), 7.74 (1H, d, J=2.5 Hz), 8.25 (1H, s).

ESI/MS: 319 [M+Na]⁺.

Elemental Analysis for C₁₆H₁₃FN₄O

Calcd.: C, 64.86; H, 4.42; N, 18.91

Found : C, 64.75; H, 4.52; N, 18.95

Example 7

5-(2-Amino-4-phenyl-5-pyrimidinyl)-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Example 3.

mp: > 250°C (90% EtOH).

NMR (DMSO-d₆, δ): 1.09 (6H, d, J=6.9 Hz), 4.89-5.02 (1H, m), 6.27 (1H, d, J=9.3 Hz), 6.81 (2H, s), 7.10 (1H, dd, J=9.3, 2.5 Hz), 7.37 (6H, brd.s), 8.29 (1H, s).

ESI/MS: 329 [M+Na]⁺.

Elemental Analysis for C₁₈H₁₈N₄O

Calcd.: C, 70.57; H, 5.92; N, 18.29

Found : C, 70.47; H, 5.94; N, 18.36

Example 8

5-(2-Amino-4-phenyl-5-pyrimidinyl)-1-ethyl-2(1H)-pyridinone was obtained according to a similar manner to that of Example 3.

mp: 240-241°C (95% EtOH).

NMR (DMSO-d₆, δ): 1.12 (3H, t, J=7.1 Hz), 3.84 (2H, q, J=7.1 Hz), 6.21 (1H, d, J=9.3 Hz), 6.82 (2H, brd. s), 6.95 (1H, dd, J=9.3, 2.5 Hz), 7.34-7.43 (5H, m), 7.57 (1H, d, J=2.5 Hz), 8.28 (1H, s).

ESI/MS: 315 [M+Na]⁺.

Elemental Analysis for C₁₇H₁₆N₄O

Calcd.: C, 69.85; H, 5.52; N, 19.17

Found : C, 69.49; H, 5.53; N, 19.05

Example 9

5-(2-Amino-4-phenyl-5-pyrimidinyl)-1-methyl-2(1H)-pyridinone was obtained according to a similar manner to that of Example 3.

mp: 209-210°C (90% EtOH).

NMR (DMSO- d_6 , δ): 3.41 (3H, s), 6.17 (1H, d, $J=9.3$ Hz), 6.80-6.86 (3H, m), 7.33-7.47 (5H, m), 7.73 (1H, d, $J=2.5$ Hz), 8.25 (1H, s).

ESI/MS: 301 $[M+Na]^+$.

Elemental Analysis for $C_{16}H_{14}N_4O \cdot 0.5H_2O$

Calcd.: C, 66.88; H, 5.27; N, 19.50

Found : C, 66.90; H, 5.24; N, 19.52

Example 10

5-[2-Amino-4-(4-fluorophenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 4.

mp: 255-257°C (90% EtOH).

Example 11

5-(2-Amino-4-phenyl-5-pyrimidinyl)-1-ethyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 4.

mp: 240-241°C (95% EtOH)

Example 12

5-[2-Amino-4-(2-methoxyphenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 4.

mp: 213-214°C (95% EtOH)

NMR (DMSO- d_6 , δ): 1.11 (6H, d, $J=6.7$ Hz), 3.66 (3H, s), 4.90-5.04 (1H, m), 6.28 (1H, d, $J=9.3$ Hz), 6.82 (2H, br s), 6.89-6.97 (3H, m), 7.09 (1H, dd, $J=9.3, 2.5$ Hz), 7.24-7.32 (1H, m), 7.40 (1H, d, $J=2.5$ Hz), 8.29 (1H, s)

ESI/MS: 337 $[M+H]^+$, 359 $[M+Na]^+$

Example 13

5-[2-Amino-4-(3-methoxyphenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 4.

mp: 212-213°C (95% EtOH)

NMR (DMSO- d_6 , δ): 1.11 (6H, d, $J=6.8$ Hz), 3.66 (3H, s), 4.91-5.04 (1H, m), 6.28 (1H, d, $J=9.3$ Hz), 6.82 (2H, br s), 6.89-6.97 (3H, m), 7.09 (1H, dd, $J=9.3, 2.5$ Hz), 7.24-7.32 (1H, m), 7.40 (1H, d, $J=2.5$ Hz), 8.29 (1H, s)

ESI/MS: 337 $[M+H]^+$, 359 $[M+Na]^+$

Example 14

5-[2-Amino-4-(4-methoxyphenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 4.

mp: 226-227°C (95% EtOH)

NMR (DMSO- d_6 , δ): 1.16 (6H, d, $J=6.8$ Hz), 3.75 (3H, s), 4.93-5.07 (1H, m), 6.28 (1H, d, $J=9.3$ Hz), 6.76 (2H, br s), 6.89-6.96 (2H, m), 7.06 (1H, dd, $J=9.3, 2.5$ Hz), 7.33-7.40 (2H, m), 7.46 (1H, d, $J=2.5$ Hz), 8.24 (1H, s)

ESI/MS: 337 $[M+H]^+$, 359 $[M+Na]^+$

Example 15

5-[2-Amino-4-(2-fluorophenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 4.

mp: > 270°C (95% EtOH)

NMR (DMSO- d_6 , δ): 1.01 (6H, d, $J=6.8$ Hz), 4.84-4.98 (1H, m), 6.27 (1H, d, $J=9.1$ Hz), 6.89 (2H, br s), 7.14-7.32 (4H, m), 7.41-7.51 (2H, m), 8.33 (1H, s)

ESI/MS: 325 $[M+H]^+$, 347 $[M+Na]^+$

Example 16

5-[2-Amino-4-(3-fluorophenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Preparation 4.

mp: 250-251°C (95% EtOH)

NMR (DMSO- d_6 , δ): 1.11 (6H, d, $J=6.7$ Hz), 4.91-5.04 (1H, m), 6.30 (1H, d, $J=9.3$ Hz), 6.88 (2H, br s), 7.11-7.24 (4H, m), 7.38-7.42 (2H, m), 8.32 (1H, s)

ESI/MS: 325 [M+H]⁺, 347 [M+Na]⁺

Example 17

To a suspension of 5-[2-amino-4-(2-methoxyphenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone (457 mg) in CH₂Cl₂ (9 ml) was added boron tribromide (1.70 g) under ice cooling and the mixture was allowed to stand overnight at 25°C. The reaction mixture was quenched with water, and the CH₂Cl₂ was removed under reduced pressure. The aqueous solution was neutralized with saturated NaHCO₃ solution. Precipitates were collected by filtration, washed with water and dried to give 390 mg of colorless solid, which was triturated with hot MeOH, cooled to 25°C, filtered and dried to afford 5-[2-amino-4-(2-hydroxyphenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone (342 mg) as colorless crystals.

mp: > 200°C (MeOH)

NMR (DMSO-d₆, δ): 1.12 (6H, d, J=6.8 Hz), 4.90-5.01 (1H, m), 6.28 (1H, d, J=9.3 Hz), 6.71-6.82 (5H, m), 7.07-7.18 (2H, m), 7.37 (1H, d, J=2.4 Hz), 8.27 (1H, s), 9.52 (1H, br s)

ESI/MS: 323 [M+H]⁺, 345 [M+Na]⁺

Example 18

5-[2-Amino-4-(3-hydroxyphenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Example 17.

mp: > 200°C (MeOH)

NMR (DMSO-d₆, δ): 1.12 (6H, d, J=6.8 Hz), 4.91-5.04 (1H, m), 6.28 (1H, d, J=9.3 Hz), 6.71-6.82 (5H, m), 7.08-7.18 (2H, m), 7.37 (1H, d, J=2.4 Hz), 8.27 (1H, s), 9.52 (1H, br s)

ESI/MS: 323 [M+H]⁺, 345 [M+Na]⁺

Example 19

A mixture of 5-[2-amino-4-(3-hydroxyphenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone (141 mg), triphenylphosphine (172 mg), tert-butyl 4-hydroxy-1-piperidinecarboxylate (114 mg), and diethylazodicarboxylate (114 mg) in THF (1.4 ml) was stirred

at 25°C overnight. Solvent was removed under reduced pressure and the residue was partitioned between water and CHCl₃. After an additional extraction with CHCl₃, the combined extracts were washed with brine, dried over MgSO₄ and concentrated under reduced pressure. The residue was dissolved in dioxane (5 ml) and 4N HCl in dioxane (2 ml) was added under ice cooling and stirred at 0 ~ 25°C for 7 hours. The reaction mixture was poured into water and was made basic with 1N NaOH. The mixture was extracted twice with EtOAc and the combined extracts were washed with brine, dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CHCl₃-MeOH, 80:1) to afford an oil (111 mg), which was dissolved in EtOAc and 4N HCl in dioxane was added. Precipitates were collected by filtration, washed with EtOAc and dried to give 5-{2-amino-4-[3-(4-piperidinyloxy)phenyl]-5-pyrimidinyl}-1-isopropyl-2(1H)-pyridinone dihydrochloride (79.4 mg) as a yellow solid. mp: 128°C (decomp.)

NMR (DMSO-d₆, δ): 1.11 (6H, d, J=6.7 Hz), 1.60-1.81 (2H, m), 1.91-2.08 (2H, m), 2.84-3.30 (4H, m), 4.52 (1H, m), 4.88-5.01 (1H, m), 6.31 (1H, d, J=9.3 Hz), 6.97-7.04 (2H, m), 7.12 (1H, dd, J=9.3, 2.4 Hz), 7.34 (1H, t, J=7.9 Hz), 7.43 (1H, d, J=2.4 Hz), 7.58-7.68 (2H, m), 7.79-7.89 (2H, m), 8.42 (1H, s), 9.02 (2H, m).

ESI/MS: 406 [M+H]⁺

Example 20

5-{2-Amino-4-[3-(2-aminoethoxy)phenyl]-5-pyrimidinyl}-1-isopropyl-2(1H)-pyridinone dihydrochloride was obtained according to a similar manner to that of Example 19.

mp: > 200°C (EtOAc)

NMR (DMSO-d₆, δ): 1.12 (6H, d, J=6.7 Hz), 2.81 (2H, t, J=5.8 Hz), 3.81 (2H, t, J=5.8 Hz), 4.91-5.04 (1H, m), 6.28 (1H, d, J=9.3 Hz), 6.89-6.94 (5H, m), 7.09 (1H, dd, J=9.3, 2.5 Hz), 7.26 (1H, t, J=7.8 Hz), 7.41 (1H, d, J=2.5 Hz), 8.29 (1H, s)

ESI/MS: 366 [M+H]⁺, 388 [M+Na]⁺

Example 21

5-[2-Amino-4-(4-hydroxyphenyl)-5-pyrimidinyl]-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Example 17.

mp: > 200°C (MeOH)

NMR (DMSO-d₆, δ): 1.17 (6H, d, J=6.8 Hz), 4.93-5.06 (1H, m), 6.28 (1H, d, J=9.3 Hz), 6.69-6.74 (4H, m), 7.06 (1H, dd, J=9.3, 2.5 Hz), 7.25 (2H, d, J=8.6 Hz), 7.44 (1H, d, J=2.5 Hz), 8.20 (1H, s), 9.77 (1H, br)

ESI/MS: 323 [M+H]⁺, 345 [M+Na]⁺

Example 22

5-(2-Amino-4-methyl-6-phenyl-5-pyrimidinyl)-2(1H)-pyridinone was obtained according to a similar manner to that of Example 1.

mp: > 200°C (EtOH)

NMR (DMSO-d₆, δ): 2.18 (3H, s), 6.23 (1H, d, J=9.3 Hz), 6.66 (2H, br s), 7.01 (1H, d, J=2.5 Hz), 7.20 (1H, dd, J=9.3, 2.5 Hz), 7.29 (5H, s), 11.52 (1H, br)

ESI/MS: 279 [M+H]⁺, 301 [M+Na]⁺

Example 23

5-(2-Amino-4-methyl-6-phenyl-5-pyrimidinyl)-1-methyl-2(1H)-pyridinone was obtained according to a similar manner to that of Example 3.

mp: > 200°C (EtOAc-EtOH)

NMR (DMSO-d₆, δ): 2.19 (3H, s), 3.14 (3H, s), 6.27 (1H, d, J=9.3 Hz), 6.68 (2H, br s), 7.13 (1H, dd, J=9.3, 2.5 Hz), 7.29 (5H, d, J=3.9 Hz), 7.47 (1H, d, J=2.5 Hz)

ESI/MS: 293 [M+H]⁺, 315 [M+Na]⁺

Example 24

5-(2-Amino-4-methyl-6-phenyl-5-pyrimidinyl)-1-ethyl-

2(1H)-pyridinone was obtained according to a similar manner to that of Example 3.

mp: > 200°C (EtOAc)

NMR (DMSO-d₆, δ): 0.95 (3H, t, J=7.1 Hz), 2.21 (3H, s), 3.74 (2H, br), 6.29 (1H, d, J=9.3 Hz), 6.69 (2H, br s), 7.20 (1H, dd, J=9.3, 2.5 Hz), 7.28 (5H, s), 7.33 (1H, d, J=2.5 Hz)

ESI/MS: 307 [M+H]⁺, 329 [M+Na]⁺

Example 25

5-(2-Amino-4-methyl-6-phenyl-5-pyrimidinyl)-1-isopropyl-2(1H)-pyridinone was obtained according to a similar manner to that of Example 3.

mp: > 200°C (EtOAc)

NMR (CDCl₃, δ): 1.01 (6H, br, 2.34 (3H, s), 5.11-5.18 (1H, m), 5.22 (2H, s), 6.58 (1H, d, J=9.3 Hz), 6.75 (1H, d, J=2.5 Hz), 7.18 (1H, dd, J=9.3, 2.5 Hz), 7.24-7.29 (5H, m)

ESI/MS: 321 [M+H]⁺, 343 [M+Na]⁺

Example 26

A solution of 4-(4-fluorophenyl)-6-methoxy-5-{6-[(4-methoxybenzyl)oxy]-3-pyridyl}-2-pyrimidinamine in AcOH (7 ml) was hydrogenated over 10% Pd/C (150 mg) at 25°C (1 atm.) for 8 hours. Pd/C was removed by filtration, washed with a mixture of CHCl₃ and MeOH and the filtrate was concentrated under reduced pressure. To the residue was added saturated NaHCO₃ and EtOAc. Insoluble material was collected by filtration, washed with water and EtOAc and dried to afford 5-[2-amino-4-(4-fluorophenyl)-6-methoxy-5-pyrimidinyl]-2(1H)-pyridinone (314 mg) as a colorless solid.

NMR (DMSO-d₆, δ): 3.29 (3H, s), 6.16 (1H, d, J=9.3 Hz), 6.92 (1H, d, J=2.5 Hz), 7.06 (1H, dd, J=9.3, 2.5 Hz), 7.09-7.18 (2H, m), 7.26-7.40 (4H, m), 11.37 (1H, br)

ESI/MS: 335 [M+Na]⁺

Example 27

5-[2-Amino-4-(4-fluorophenyl)-6-methoxy-5-pyrimidinyl]-1-isopropyl-2(1*H*)-pyridinone was obtained according to a similar manner to that of Example 3.


mp: > 200°C (EtOAc)

NMR (CDCl₃, δ): 1.06 (6H, d, J=6.8 Hz), 3.52 (3H, s), 5.09-5.23 (1H, m), 5.30 (2H, br s), 6.50 (1H, d, J=9.4 Hz), 6.94-7.03 (3H, m), 7.23-7.37

ESI/MS: 355 [M+H]⁺, 377 [M+Na]⁺

CLAIMS

1. An aminopyrimidine compound of the following formula (I).



wherein

R¹ is hydrogen, lower alkyl, cyclo(lower)alkyl which may be interrupted by an oxygen atom or aryl(lower)alkyl,
R² is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, amino(lower)alkoxy or piperidinyloxy,
R³ is hydrogen, hydroxy, lower alkyl or lower alkoxy, and
R⁴ and R⁵ are each hydrogen, lower alkyl or acyl,
or a salt thereof.

2. A compound of claim 1,

wherein

R¹ is hydrogen or lower alkyl,
R² is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, amino(lower)alkyl or piperidinyloxy,
R³ is hydrogen, lower alkyl or lower alkoxy and
R⁴ and R⁵ are each hydrogen,
or a salt thereof.

3. A compound of claim 2,

wherein

R¹ is hydrogen, methyl, ethyl, propyl or isopropyl,
R² is hydrogen, fluoro, hydroxy, methoxy, aminoethyloxy or piperidinyloxy,
R³ is hydrogen, methyl or methoxy, and
R⁴ and R⁵ are each hydrogen,

or a salt thereof.

4. A compound of claim 2,

wherein

R¹ is hydrogen or isopropyl,

R² is hydrogen or fluoro,


R³ is hydrogen, methyl or methoxy, and

R⁴ and R⁵ are each hydrogen,

or a salt thereof.

5. A process for the preparation of the aminopyrimidine compound of claim 1 or a salt thereof, which comprises,

(1) hydrolyzing a compound of the formula (IIa):




wherein

R², R³, R⁴ and R⁵ are as defined above, and

R⁶ is lower alkyl, or a salt thereof,

to give a compound of the formula (Ia):




wherein R², R³, R⁴ and R⁵ are as defined above, or a salt thereof,

(2) reacting a compound of the formula (Ia), or a salt thereof

with a compound of the formula (III):




wherein R^{1a} is lower alkyl, cyclo(lower)alkyl which may be interrupted by an oxygen atom or aryl(lower)alkyl, and Y^1 is a leaving group, or a salt thereof, to give a compound of the formula (Ib):




wherein R^2 , R^3 , R^4 , R^5 and R^{1a} are each as defined above, or a salt thereof,


(3) reacting a compound of the formula (IV):



wherein R^1 and R^2 are each as defined above, or a salt thereof, with a compound of the formula (V):




wherein R^3 is as defined above, and R^7 is lower alkyl, or a salt thereof, and further with a compound of the formula (VI):




wherein R^4 and R^5 are each as defined above, or a salt thereof, to give a compound of the formula (I), or a salt thereof,

(4) eliminating a compound of the formula (Ic):



wherein R^1 , R^3 , R^4 and R^5 are each as defined above, and R^{8a} is a lower alkyl, or a salt thereof, to give a compound of the formula (Id):




wherein R^1 , R^3 , R^4 and R^5 are each as defined above, or a salt thereof,

(5) reacting a compound of the formula (Id), or a salt thereof with a compound of the formula (VII):




wherein R^{8b} is amino(lower)alkyl or cyclo(lower)alkyl which may be interrupted by an oxygen atom, and

Y^2 is a leaving group, or a salt thereof,
to give a compound of the formula (Ie):



wherein R^1 , R^3 , R^4 and R^5 are each as defined above, and R^{8b} is a lower alkyl or a salt thereof,

(6) hydrogenating a compound of the formula (IIb):



wherein R^2 , R^3 , R^4 and R^5 are each as defined above, and R^9 is benzyl which is optionally substituted by suitable substituent(s), selected from the group consisting of halogen, hydroxy, lower alkyl, lower alkoxy, nitro and cyano, or a salt thereof,

to give a compound of the formula (Ia), or a salt thereof.

6. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.

7. A method for preventing or treating a disease selected from the group consisting of depression, dementia, Parkinson's disease, anxiety, pain, cerebrovascular disease, heart failure,

hypertension, circulatory insufficiency, post-resuscitation, asystole, bradyarrhythmia, electro-mechanical dissociation, hemodynamic collapse, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal insufficiency), renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer, pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack and angina pectoris, which comprises administering the compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.

8. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as a medicament.

9. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as an adenosine antagonist.

10. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as an A₁ receptor and A₂ receptor dual antagonist.

11. A process for preparing a pharmaceutical composition which comprises admixing the compound of claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier.

12. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for the production of a pharmaceutical composition for the therapy of diseases on which an adenosine antagonist is therapeutically effective.

13. A method for evaluation of adenosine antagonism which comprises use of compound of claim 1 or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 03/10360

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/04 A61K31/506 A61P25/16 A61P25/22 A61P25/24
A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03 035639 A (EISAI CO., LTD., JAPAN) 1 May 2003 (2003-05-01) see abstract claims 1,11,13; examples 21-24	1-13
A	WO 02 14282 A (ASANO OSAMU ;UEDA MASATO (JP); EISAI CO LTD (JP); HARADA HITOSHI () 21 February 2002 (2002-02-21) cited in the application see e.g. example 183 & EP 1 308 441 A 7 May 2003 (2003-05-07)	1-13
A	WO 01 62233 A (HOFFMANN LA ROCHE) 30 August 2001 (2001-08-30) claim 1	1-13

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

10 December 2003

Date of mailing of the international search report

19/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Traegler-Goeldel, M

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP 03/10360

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 7 to 10 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 03/10360

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03035639	A	01-05-2003	WO 03035639 A1	01-05-2003
WO 0214282	A	21-02-2002	AU 7774101 A	25-02-2002
			CA 2417846 A1	30-01-2003
			CN 1446202 T	01-10-2003
			EP 1308441 A1	07-05-2003
			WO 0214282 A1	21-02-2002
			NO 20030637 A	10-04-2003
WO 0162233	A	30-08-2001	AU 5464301 A	03-09-2001
			BR 0108611 A	06-05-2003
			CA 2398274 A1	30-08-2001
			CN 1438890 T	27-08-2003
			CZ 20023199 A3	14-05-2003
			WO 0162233 A2	30-08-2001
			EP 1261327 A2	04-12-2002
			HU 0300029 A2	28-05-2003
			JP 2003523380 T	05-08-2003
			NO 20024006 A	22-08-2002
			US 2001027196 A1	04-10-2001